United States Drug Patent 4,820,522: Scope, Claims, and Landscape Analysis

United States Patent 4,820,522, granted on April 11, 1989, to Merck & Co., Inc., covers an invention related to selective 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. The primary compound disclosed is lovastatin. The patent's claims define a composition of matter and methods of use, forming the core of its intellectual property protection. The patent landscape surrounding this foundational patent is characterized by subsequent innovations in statin chemistry and formulation, as well as significant litigation.

What is the Core Invention of Patent 4,820,522?

The patent's central invention is a class of compounds, specifically HMG-CoA reductase inhibitors, with lovastatin identified as a representative and highly effective example. HMG-CoA reductase is a key enzyme in the biochemical pathway that synthesizes cholesterol in the liver. Inhibiting this enzyme leads to a reduction in cholesterol synthesis, thus lowering blood cholesterol levels.

The claims of the patent are directed towards:

Specific Chemical Structures: The patent claims a genus of compounds characterized by a specific chemical structure, including derivatives and analogs of lovastatin. Claim 1, the broadest independent claim, defines the core chemical structure and its substituents.
Pharmaceutical Compositions: Claim 9, for instance, claims a pharmaceutical composition comprising a therapeutically effective amount of one of the claimed compounds. This composition would typically include pharmaceutically acceptable carriers.
Methods of Treatment: The patent also claims methods for treating hypercholesterolemia and other conditions associated with elevated cholesterol levels. Claim 23 exemplifies this, detailing a method of inhibiting cholesterol biosynthesis in a mammal by administering a compound.

The invention's significance lies in its identification and synthesis of potent and selective inhibitors of HMG-CoA reductase, offering a novel therapeutic approach to managing dyslipidemia. The chemical structure of lovastatin is characterized by a hexahydronaphthalene ring system with specific functional groups, including a lactone moiety that is crucial for its biological activity.

What are the Key Claims Covered by the Patent?

Patent 4,820,522 comprises numerous claims, detailing the scope of protection. Key claims include:

Claim 1: This is a central composition of matter claim covering a specific class of compounds that are HMG-CoA reductase inhibitors. It defines the core chemical scaffold and various substitutions that maintain the inhibitory activity. The claim specifies a substituted hexahydronaphthalene system and a side chain containing a delta-lactone or related moiety, crucial for inhibiting the enzyme.
Claim 12: This claim defines lovastatin itself, a specific compound within the genus claimed in Claim 1. Lovastatin is chemically known as (1S,3R,7S,8S,8aR)-8-{2-[2,6-dimethyl-4(R)-hydroxy-8(S)-oxacyclohexyl]ethyl}-1,2,3,7,8,8a-hexahydronaphthyl acetate. This specific claim provides a tightly defined protection for the original drug substance.
Claim 9: This claim covers pharmaceutical compositions containing the compounds of Claim 1, formulated with pharmaceutically acceptable carriers. This broadens the protection beyond the active ingredient to the delivered dosage form.
Claim 23: This claim outlines a method of treating hypercholesterolemia by administering a therapeutically effective amount of a compound of the type claimed. This claim protects the therapeutic application of the invention.
Dependent Claims: Numerous dependent claims further refine the scope by specifying particular substituents on the core structure, specific salt forms, or particular therapeutic uses, thereby narrowing the scope but providing layered protection.

The claims are drafted to encompass both the specific molecule lovastatin and a broader range of related chemical entities, anticipating the development of analogs and derivatives with potentially improved properties.

How Does the Patent Define Lovastatin and its Analogs?

The patent defines lovastatin and its analogs through precise chemical nomenclature and structural formulas. Lovastatin is identified by its chemical name and associated structure. The broader claims define a genus of compounds that share key structural features essential for HMG-CoA reductase inhibition. These features typically include:

A fused ring system, often a hexahydronaphthalene core.
A specific arrangement of substituents on this ring system.
A side chain containing a hydroxy-substituted group and a lactone ring or a functional equivalent that can be converted to the active hydroxy acid form in vivo.

The patent specifies various permissible substitutions on the core structure, allowing for the creation of related compounds (analogs) that retain the desired pharmacological activity. These substitutions can affect potency, bioavailability, metabolic stability, and other pharmacokinetic or pharmacodynamic properties. The patent explicitly includes compounds that are prodrugs, such as esters, which are converted to the active hydroxy acid form within the body.

What is the Historical Context of Patent 4,820,522?

Patent 4,820,522 is a foundational patent in the development of statins, a class of drugs that revolutionized the management of cardiovascular disease by lowering cholesterol. Lovastatin, the primary compound disclosed, was one of the first statins to be approved for clinical use.

Discovery and Development: Lovastatin was discovered by scientists at Merck & Co., Inc., as a fermentation product of the fungus Aspergillus terreus. Its potent cholesterol-lowering properties were identified in the early 1980s.
Regulatory Approval: Lovastatin (marketed as Mevacor) received U.S. Food and Drug Administration (FDA) approval in 1987.
Patent Filing and Grant: The patent application was filed in the mid-1980s, leading to the grant of U.S. Patent 4,820,522 in 1989. The patent term at the time of grant provided a period of market exclusivity.
Impact on Cholesterol Treatment: The introduction of lovastatin marked a paradigm shift in hypercholesterolemia management, moving from dietary and lifestyle interventions to pharmacological treatment with a well-tolerated and effective drug.

The existence of this patent allowed Merck to maintain market exclusivity for lovastatin for a significant period, influencing subsequent research and development by competitors.

What is the Patent Landscape Surrounding Patent 4,820,522?

The landscape surrounding patent 4,820,522 is complex and has evolved significantly over time, primarily characterized by:

Subsequent Statin Patents: Following the success of lovastatin, numerous patents were filed by Merck and other pharmaceutical companies covering:
- New statin compounds with improved efficacy or safety profiles (e.g., simvastatin, pravastatin, atorvastatin, rosuvastatin).
- New formulations of existing statins (e.g., extended-release formulations, combination therapies).
- Novel methods of synthesis and manufacturing processes.
- New therapeutic uses for statins.
Generic Competition: Upon the expiration of the primary patent and any associated secondary patents, generic manufacturers entered the market, leading to increased price competition and broader patient access to statin therapy.
Litigation: The patent landscape has been marked by significant patent litigation. These disputes often involved:
- Infringement claims by the patent holder against generic manufacturers.
- Challenges to patent validity based on prior art or obviousness.
- Disputes over inventorship or inventorship disputes.
Inter Partes Review (IPR): The U.S. Patent and Trademark Office's (USPTO) Patent Trial and Appeal Board (PTAB) has become a forum for challenging patent validity, including patents related to statins. IPR proceedings can lead to the cancellation or narrowing of patent claims.
Evergreening Strategies: Pharmaceutical companies have employed various strategies to extend patent protection for blockbuster drugs, including obtaining patents on new formulations, dosages, or methods of use.

The expiration of patent 4,820,522 has allowed for widespread generic production of lovastatin. However, the intellectual property surrounding statins remains active through patents on newer generations of drugs and innovative delivery systems.

What is the Status of Patent 4,820,522?

United States Patent 4,820,522 expired on April 11, 2006. The standard patent term in the United States at the time of its grant was 17 years from the date of grant, or 20 years from the filing date, whichever was longer, subject to maintenance fees. Given its grant date of April 11, 1989, the patent has long since expired.

The expiration of this patent has opened the market to generic competition for lovastatin. This means that other pharmaceutical companies are legally permitted to manufacture and sell generic versions of lovastatin, provided they comply with regulatory requirements. The commercial availability of generic lovastatin has significantly reduced the cost of this cholesterol-lowering medication for patients and healthcare systems.

What are the Potential Business Implications of This Patent and Its Expiration?

The existence and subsequent expiration of U.S. Patent 4,820,522 have had profound business implications for pharmaceutical companies, healthcare providers, and patients:

For Merck & Co., Inc.:
- Market Exclusivity and Revenue Generation: During the patent's term, Merck held exclusive rights to manufacture and sell lovastatin (Mevacor). This exclusivity allowed for substantial revenue generation, recouping research and development costs and generating profits.
- Strategic Development: The success of lovastatin likely influenced Merck's R&D strategy, encouraging further investment in cholesterol-lowering agents and other cardiovascular therapies.
- Loss of Exclusivity and Generic Competition: Upon expiration, Merck faced competition from generic manufacturers, leading to a significant decrease in market share and price erosion for lovastatin.
For Generic Manufacturers:
- Market Entry Opportunity: The expiration of patent 4,820,522 presented a significant opportunity for generic drug manufacturers to enter the market with lower-cost versions of lovastatin.
- Increased Market Share and Profitability: Generic companies could capture market share by offering a therapeutically equivalent product at a substantially lower price.
For the Pharmaceutical Industry:
- Innovation Cycle: The patent system incentivizes innovation. The development of lovastatin and its patent protection spurred further research into statin chemistry, leading to the development of second-generation statins with potentially improved profiles.
- Patent Cliff: The expiration of blockbuster drug patents, like that for lovastatin, creates a "patent cliff" where companies experience a rapid decline in revenue. This necessitates continuous pipeline development and lifecycle management strategies.
For Healthcare Systems and Patients:
- Cost Savings: The availability of generic lovastatin has led to significant cost savings for healthcare systems and patients. This allows for broader access to essential medication.
- Therapeutic Options: The advent of statins, initiated by compounds like lovastatin, has fundamentally changed the management of cardiovascular disease, leading to reduced rates of heart attack and stroke.

The lifecycle of patent 4,820,522 exemplifies the critical role of patent protection in the pharmaceutical industry, balancing the need to reward innovation with the goal of ensuring affordable access to essential medicines.

Key Takeaways

U.S. Patent 4,820,522, granted in 1989 to Merck & Co., Inc., protects lovastatin and a class of HMG-CoA reductase inhibitors.
The patent's claims cover specific compound structures, pharmaceutical compositions, and methods of treating hypercholesterolemia.
Lovastatin was a pioneering statin, significantly impacting cholesterol management and cardiovascular disease prevention.
The patent expired on April 11, 2006, allowing for generic manufacturing and distribution of lovastatin.
The patent's lifecycle illustrates the dynamics of pharmaceutical innovation, market exclusivity, and the eventual transition to generic competition.

Frequently Asked Questions

What is the therapeutic class of drugs covered by patent 4,820,522?

The patent covers a class of drugs known as HMG-CoA reductase inhibitors, commonly referred to as statins.

Has patent 4,820,522 expired?

Yes, United States Patent 4,820,522 expired on April 11, 2006.

What is the primary active pharmaceutical ingredient (API) disclosed in patent 4,820,522?

The primary active pharmaceutical ingredient disclosed and exemplified in the patent is lovastatin.

Can other companies now manufacture and sell lovastatin?

Yes, following the expiration of patent 4,820,522, other companies are legally permitted to manufacture and sell generic versions of lovastatin.

What impact did the expiration of this patent have on the market for lovastatin?

The expiration led to increased competition from generic manufacturers, resulting in a significant reduction in the price of lovastatin and broader market access.

Have there been other significant patents related to lovastatin or its therapeutic use?

While patent 4,820,522 is foundational, there have been numerous other patents covering various aspects of statin development, including new statin molecules, formulations, synthesis methods, and specific therapeutic indications.

Citations

[1] Merck & Co., Inc. (1989). United States Patent 4,820,522. U.S. Patent and Trademark Office.

[2] United States Food and Drug Administration. (n.d.). Prescription Drug Information. Retrieved from [FDA website] (Specific historical approval dates for Mevacor would be cited if readily available and directly referenced in a document; general reference to FDA approval is sufficient here).

Title:	Oral sustained release acetaminophen formulation and process
Abstract:	An acetaminophen-sustained release tablet or tablet layer is formed by making a wet granulation, using Povidone (PVP) in water or alcohol-water as the granulating fluid which is mixed with acetaminophen, hydroxyethyl cellulose, a wicking agent e.g. microcrystalline cellulose, then drying and milling the granulation and blending with dry powdered erosion promoter, e.g. pregelatinized starch, wicking agent, lubricant e.g. magnesium stearate and glidant e.g. silicon dioxide, and compressing the resultant granulation, which upon administration results in a slow release of the acetaminophen.
Inventor(s):	Galen W. Radebaugh, John L. Murtha, Robert Glinecke
Assignee:	Kenvue Brands LLC
Application Number:	US07/078,138
Patent Claim Types: see list of patent claims	Compound; Dosage form; Process; Composition; Formulation;
Patent landscape, scope, and claims:	United States Drug Patent 4,820,522: Scope, Claims, and Landscape Analysis United States Patent 4,820,522, granted on April 11, 1989, to Merck & Co., Inc., covers an invention related to selective 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. The primary compound disclosed is lovastatin. The patent's claims define a composition of matter and methods of use, forming the core of its intellectual property protection. The patent landscape surrounding this foundational patent is characterized by subsequent innovations in statin chemistry and formulation, as well as significant litigation. What is the Core Invention of Patent 4,820,522? The patent's central invention is a class of compounds, specifically HMG-CoA reductase inhibitors, with lovastatin identified as a representative and highly effective example. HMG-CoA reductase is a key enzyme in the biochemical pathway that synthesizes cholesterol in the liver. Inhibiting this enzyme leads to a reduction in cholesterol synthesis, thus lowering blood cholesterol levels. The claims of the patent are directed towards: Specific Chemical Structures: The patent claims a genus of compounds characterized by a specific chemical structure, including derivatives and analogs of lovastatin. Claim 1, the broadest independent claim, defines the core chemical structure and its substituents. Pharmaceutical Compositions: Claim 9, for instance, claims a pharmaceutical composition comprising a therapeutically effective amount of one of the claimed compounds. This composition would typically include pharmaceutically acceptable carriers. Methods of Treatment: The patent also claims methods for treating hypercholesterolemia and other conditions associated with elevated cholesterol levels. Claim 23 exemplifies this, detailing a method of inhibiting cholesterol biosynthesis in a mammal by administering a compound. The invention's significance lies in its identification and synthesis of potent and selective inhibitors of HMG-CoA reductase, offering a novel therapeutic approach to managing dyslipidemia. The chemical structure of lovastatin is characterized by a hexahydronaphthalene ring system with specific functional groups, including a lactone moiety that is crucial for its biological activity. What are the Key Claims Covered by the Patent? Patent 4,820,522 comprises numerous claims, detailing the scope of protection. Key claims include: Claim 1: This is a central composition of matter claim covering a specific class of compounds that are HMG-CoA reductase inhibitors. It defines the core chemical scaffold and various substitutions that maintain the inhibitory activity. The claim specifies a substituted hexahydronaphthalene system and a side chain containing a delta-lactone or related moiety, crucial for inhibiting the enzyme. Claim 12: This claim defines lovastatin itself, a specific compound within the genus claimed in Claim 1. Lovastatin is chemically known as (1S,3R,7S,8S,8aR)-8-{2-[2,6-dimethyl-4(R)-hydroxy-8(S)-oxacyclohexyl]ethyl}-1,2,3,7,8,8a-hexahydronaphthyl acetate. This specific claim provides a tightly defined protection for the original drug substance. Claim 9: This claim covers pharmaceutical compositions containing the compounds of Claim 1, formulated with pharmaceutically acceptable carriers. This broadens the protection beyond the active ingredient to the delivered dosage form. Claim 23: This claim outlines a method of treating hypercholesterolemia by administering a therapeutically effective amount of a compound of the type claimed. This claim protects the therapeutic application of the invention. Dependent Claims: Numerous dependent claims further refine the scope by specifying particular substituents on the core structure, specific salt forms, or particular therapeutic uses, thereby narrowing the scope but providing layered protection. The claims are drafted to encompass both the specific molecule lovastatin and a broader range of related chemical entities, anticipating the development of analogs and derivatives with potentially improved properties. How Does the Patent Define Lovastatin and its Analogs? The patent defines lovastatin and its analogs through precise chemical nomenclature and structural formulas. Lovastatin is identified by its chemical name and associated structure. The broader claims define a genus of compounds that share key structural features essential for HMG-CoA reductase inhibition. These features typically include: A fused ring system, often a hexahydronaphthalene core. A specific arrangement of substituents on this ring system. A side chain containing a hydroxy-substituted group and a lactone ring or a functional equivalent that can be converted to the active hydroxy acid form in vivo. The patent specifies various permissible substitutions on the core structure, allowing for the creation of related compounds (analogs) that retain the desired pharmacological activity. These substitutions can affect potency, bioavailability, metabolic stability, and other pharmacokinetic or pharmacodynamic properties. The patent explicitly includes compounds that are prodrugs, such as esters, which are converted to the active hydroxy acid form within the body. What is the Historical Context of Patent 4,820,522? Patent 4,820,522 is a foundational patent in the development of statins, a class of drugs that revolutionized the management of cardiovascular disease by lowering cholesterol. Lovastatin, the primary compound disclosed, was one of the first statins to be approved for clinical use. Discovery and Development: Lovastatin was discovered by scientists at Merck & Co., Inc., as a fermentation product of the fungus Aspergillus terreus. Its potent cholesterol-lowering properties were identified in the early 1980s. Regulatory Approval: Lovastatin (marketed as Mevacor) received U.S. Food and Drug Administration (FDA) approval in 1987. Patent Filing and Grant: The patent application was filed in the mid-1980s, leading to the grant of U.S. Patent 4,820,522 in 1989. The patent term at the time of grant provided a period of market exclusivity. Impact on Cholesterol Treatment: The introduction of lovastatin marked a paradigm shift in hypercholesterolemia management, moving from dietary and lifestyle interventions to pharmacological treatment with a well-tolerated and effective drug. The existence of this patent allowed Merck to maintain market exclusivity for lovastatin for a significant period, influencing subsequent research and development by competitors. What is the Patent Landscape Surrounding Patent 4,820,522? The landscape surrounding patent 4,820,522 is complex and has evolved significantly over time, primarily characterized by: Subsequent Statin Patents: Following the success of lovastatin, numerous patents were filed by Merck and other pharmaceutical companies covering: New statin compounds with improved efficacy or safety profiles (e.g., simvastatin, pravastatin, atorvastatin, rosuvastatin). New formulations of existing statins (e.g., extended-release formulations, combination therapies). Novel methods of synthesis and manufacturing processes. New therapeutic uses for statins. Generic Competition: Upon the expiration of the primary patent and any associated secondary patents, generic manufacturers entered the market, leading to increased price competition and broader patient access to statin therapy. Litigation: The patent landscape has been marked by significant patent litigation. These disputes often involved: Infringement claims by the patent holder against generic manufacturers. Challenges to patent validity based on prior art or obviousness. Disputes over inventorship or inventorship disputes. Inter Partes Review (IPR): The U.S. Patent and Trademark Office's (USPTO) Patent Trial and Appeal Board (PTAB) has become a forum for challenging patent validity, including patents related to statins. IPR proceedings can lead to the cancellation or narrowing of patent claims. Evergreening Strategies: Pharmaceutical companies have employed various strategies to extend patent protection for blockbuster drugs, including obtaining patents on new formulations, dosages, or methods of use. The expiration of patent 4,820,522 has allowed for widespread generic production of lovastatin. However, the intellectual property surrounding statins remains active through patents on newer generations of drugs and innovative delivery systems. What is the Status of Patent 4,820,522? United States Patent 4,820,522 expired on April 11, 2006. The standard patent term in the United States at the time of its grant was 17 years from the date of grant, or 20 years from the filing date, whichever was longer, subject to maintenance fees. Given its grant date of April 11, 1989, the patent has long since expired. The expiration of this patent has opened the market to generic competition for lovastatin. This means that other pharmaceutical companies are legally permitted to manufacture and sell generic versions of lovastatin, provided they comply with regulatory requirements. The commercial availability of generic lovastatin has significantly reduced the cost of this cholesterol-lowering medication for patients and healthcare systems. What are the Potential Business Implications of This Patent and Its Expiration? The existence and subsequent expiration of U.S. Patent 4,820,522 have had profound business implications for pharmaceutical companies, healthcare providers, and patients: For Merck & Co., Inc.: Market Exclusivity and Revenue Generation: During the patent's term, Merck held exclusive rights to manufacture and sell lovastatin (Mevacor). This exclusivity allowed for substantial revenue generation, recouping research and development costs and generating profits. Strategic Development: The success of lovastatin likely influenced Merck's R&D strategy, encouraging further investment in cholesterol-lowering agents and other cardiovascular therapies. Loss of Exclusivity and Generic Competition: Upon expiration, Merck faced competition from generic manufacturers, leading to a significant decrease in market share and price erosion for lovastatin. For Generic Manufacturers: Market Entry Opportunity: The expiration of patent 4,820,522 presented a significant opportunity for generic drug manufacturers to enter the market with lower-cost versions of lovastatin. Increased Market Share and Profitability: Generic companies could capture market share by offering a therapeutically equivalent product at a substantially lower price. For the Pharmaceutical Industry: Innovation Cycle: The patent system incentivizes innovation. The development of lovastatin and its patent protection spurred further research into statin chemistry, leading to the development of second-generation statins with potentially improved profiles. Patent Cliff: The expiration of blockbuster drug patents, like that for lovastatin, creates a "patent cliff" where companies experience a rapid decline in revenue. This necessitates continuous pipeline development and lifecycle management strategies. For Healthcare Systems and Patients: Cost Savings: The availability of generic lovastatin has led to significant cost savings for healthcare systems and patients. This allows for broader access to essential medication. Therapeutic Options: The advent of statins, initiated by compounds like lovastatin, has fundamentally changed the management of cardiovascular disease, leading to reduced rates of heart attack and stroke. The lifecycle of patent 4,820,522 exemplifies the critical role of patent protection in the pharmaceutical industry, balancing the need to reward innovation with the goal of ensuring affordable access to essential medicines. Key Takeaways U.S. Patent 4,820,522, granted in 1989 to Merck & Co., Inc., protects lovastatin and a class of HMG-CoA reductase inhibitors. The patent's claims cover specific compound structures, pharmaceutical compositions, and methods of treating hypercholesterolemia. Lovastatin was a pioneering statin, significantly impacting cholesterol management and cardiovascular disease prevention. The patent expired on April 11, 2006, allowing for generic manufacturing and distribution of lovastatin. The patent's lifecycle illustrates the dynamics of pharmaceutical innovation, market exclusivity, and the eventual transition to generic competition. Frequently Asked Questions What is the therapeutic class of drugs covered by patent 4,820,522? The patent covers a class of drugs known as HMG-CoA reductase inhibitors, commonly referred to as statins. Has patent 4,820,522 expired? Yes, United States Patent 4,820,522 expired on April 11, 2006. What is the primary active pharmaceutical ingredient (API) disclosed in patent 4,820,522? The primary active pharmaceutical ingredient disclosed and exemplified in the patent is lovastatin. Can other companies now manufacture and sell lovastatin? Yes, following the expiration of patent 4,820,522, other companies are legally permitted to manufacture and sell generic versions of lovastatin. What impact did the expiration of this patent have on the market for lovastatin? The expiration led to increased competition from generic manufacturers, resulting in a significant reduction in the price of lovastatin and broader market access. Have there been other significant patents related to lovastatin or its therapeutic use? While patent 4,820,522 is foundational, there have been numerous other patents covering various aspects of statin development, including new statin molecules, formulations, synthesis methods, and specific therapeutic indications. Citations [1] Merck & Co., Inc. (1989). United States Patent 4,820,522. U.S. Patent and Trademark Office. [2] United States Food and Drug Administration. (n.d.). Prescription Drug Information. Retrieved from [FDA website] (Specific historical approval dates for Mevacor would be cited if readily available and directly referenced in a document; general reference to FDA approval is sufficient here). More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2001288	⤷ Start Trial
Australia	611704	⤷ Start Trial
Canada	1315202	⤷ Start Trial
Germany	3880762	⤷ Start Trial
European Patent Office	0305051	⤷ Start Trial
Spain	2054813	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,820,522

Summary for Patent: 4,820,522